A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

Giles, FJ; Shan, JQ; Advani, SH; Akan, H; Aydogdu, I; Aziz, Z; Azim, HA; Bapsy, PP; Buyukkececi, F; Chaimongkol, B; Chen, PM; Cheong, SK; Ferhanoglu, B; Hamza, R; Khalid, HM; Intragumtornchai, T; Kim, SW; Kim, SY; Koc, H; Kumar, L; Kumar, R; Lei, KI; Lekhakula, A; Muthalib, A; Patel, M; Poovalingam, VP; Prayoonwiwat, W; Rana, F; Reksodiputro, AH; Ruff, P; Sagar, TG; Schwarer, AP; Song, HS; Suh, CW; Suharti, C; Supindiman, I; Tee, GY; Thamprasit, T; Villalon, AH; Wickham, NR; Wong, JE; Yalcin, A; Jootar, S

doi:10.3109/10428190009054885

A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

Giles F., Shan J., Advani S., Akan H., Aydogdu I., Aziz Z., ...More

LEUKEMIA & LYMPHOMA, vol.40, pp.95-103, 2000 (SCI-Expanded)

Publication Type: Article / Article
Volume: 40
Publication Date: 2000
Doi Number: 10.3109/10428190009054885
Journal Name: LEUKEMIA & LYMPHOMA
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.95-103
Istanbul University Affiliated: No

Abstract

The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.